O	0	6	Impact
O	7	9	of
B-intervention	10	15	rapid
I-intervention	16	23	genetic
I-intervention	24	35	counselling
I-intervention	36	39	and
I-intervention	40	47	testing
O	48	50	on
O	51	54	the
O	55	63	decision
O	64	66	to
O	67	74	undergo
O	75	84	immediate
O	85	87	or
O	88	95	delayed
O	96	108	prophylactic
O	109	119	mastectomy
O	120	122	in
O	123	128	newly
O	129	138	diagnosed
O	139	145	breast
O	146	152	cancer
O	153	161	patients
O	161	162	:
O	163	171	findings
O	172	176	from
O	177	178	a
O	179	189	randomised
O	190	200	controlled
O	201	206	trial
O	206	207	.

O	208	214	Female
O	215	221	breast
O	222	228	cancer
O	229	237	patients
O	238	242	with
O	243	244	a
O	245	250	BRCA1
O	250	251	/
O	251	252	2
O	253	261	mutation
O	262	266	have
O	267	269	an
O	270	279	increased
O	280	284	risk
O	285	287	of
O	288	301	contralateral
O	302	308	breast
O	309	315	cancer
O	315	316	.

O	317	319	We
O	320	332	investigated
O	333	336	the
O	337	343	effect
O	344	346	of
O	347	352	rapid
O	353	360	genetic
O	361	372	counselling
O	373	376	and
O	377	384	testing
O	385	386	(
O	386	390	RGCT
O	390	391	)
O	392	394	on
O	395	401	choice
O	402	404	of
O	405	412	surgery
O	412	413	.

B-eligibility	414	419	Newly
I-eligibility	420	429	diagnosed
I-eligibility	430	436	breast
I-eligibility	437	443	cancer
I-eligibility	444	452	patients
I-eligibility	453	457	with
I-eligibility	458	460	at
I-eligibility	461	466	least
I-eligibility	467	468	a
I-eligibility	469	471	10
I-eligibility	471	472	%
I-eligibility	473	477	risk
I-eligibility	478	480	of
I-eligibility	481	482	a
I-eligibility	483	488	BRCA1
I-eligibility	488	489	/
I-eligibility	489	490	2
I-eligibility	491	499	mutation
O	500	504	were
O	505	515	randomised
O	516	518	to
O	519	521	an
O	522	534	intervention
O	535	540	group
O	541	542	(
O	542	547	offer
O	548	550	of
O	551	555	RGCT
O	555	556	)
O	557	559	or
O	560	561	a
B-control	562	569	control
I-control	570	575	group
O	576	577	(
O	577	582	usual
O	583	587	care
O	587	588	;
O	589	594	ratio
O	595	596	2
O	597	598	:
O	599	600	1
O	600	601	)
O	601	602	.

O	603	610	Primary
O	611	616	study
O	617	625	outcomes
O	626	630	were
B-outcome-Measure	631	637	uptake
I-outcome-Measure	638	640	of
I-outcome-Measure	641	647	direct
I-outcome-Measure	648	657	bilateral
I-outcome-Measure	658	668	mastectomy
I-outcome-Measure	669	670	(
I-outcome-Measure	670	673	BLM
I-outcome-Measure	673	674	)
O	675	678	and
B-outcome-Measure	679	686	delayed
I-outcome-Measure	687	700	contralateral
I-outcome-Measure	701	713	prophylactic
I-outcome-Measure	714	724	mastectomy
I-outcome-Measure	725	726	(
I-outcome-Measure	726	729	CPM
I-outcome-Measure	729	730	)
O	730	731	.

O	732	739	Between
O	740	744	2008
O	745	748	and
O	749	753	2010
O	753	754	,
O	755	757	we
O	758	767	recruited
B-total-participants	768	771	265
O	772	777	women
O	777	778	.

O	779	781	On
O	782	785	the
O	786	791	basis
O	792	794	of
O	795	804	intention
O	804	805	-
O	805	807	to
O	807	808	-
O	808	813	treat
O	814	822	analyses
O	822	823	,
O	824	826	no
O	827	838	significant
O	839	844	group
O	845	856	differences
O	857	861	were
O	862	870	observed
O	871	873	in
B-outcome	874	884	percentage
I-outcome	885	887	of
I-outcome	888	896	patients
I-outcome	897	903	opting
I-outcome	904	907	for
I-outcome	908	909	a
I-outcome	910	916	direct
I-outcome	917	920	BLM
O	921	922	(
B-iv-bin-percent	922	924	14
I-iv-bin-percent	924	925	.
I-iv-bin-percent	925	926	6
I-iv-bin-percent	926	927	%
O	928	931	for
O	932	935	the
O	936	940	RGCT
O	941	946	group
O	947	949	vs
B-cv-bin-percent	950	951	9
I-cv-bin-percent	951	952	.
I-cv-bin-percent	952	953	2
I-cv-bin-percent	953	954	%
O	955	958	for
O	959	962	the
O	963	970	control
O	971	976	group
O	976	977	;
O	978	982	odds
O	983	988	ratio
O	989	990	(
O	990	992	OR
O	992	993	)
O	994	995	2
O	995	996	.
O	996	998	31
O	998	999	;
O	1000	1010	confidence
O	1011	1019	interval
O	1020	1021	(
O	1021	1023	CI
O	1023	1024	)
O	1025	1026	0
O	1026	1027	.
O	1027	1029	92
O	1029	1030	-
O	1030	1031	5
O	1031	1032	.
O	1032	1034	81
O	1034	1035	;
O	1036	1037	P
O	1037	1038	=
O	1038	1039	0
O	1039	1040	.
O	1040	1042	08
O	1042	1043	)
O	1044	1046	or
O	1047	1050	for
O	1051	1052	a
B-outcome	1053	1060	delayed
I-outcome	1061	1064	CPM
O	1065	1066	(
B-iv-bin-percent	1066	1067	4
I-iv-bin-percent	1067	1068	.
I-iv-bin-percent	1068	1069	5
I-iv-bin-percent	1069	1070	%
O	1071	1074	for
O	1075	1078	the
O	1079	1083	RGCT
O	1084	1089	group
O	1090	1092	vs
B-cv-bin-percent	1093	1094	5
I-cv-bin-percent	1094	1095	.
I-cv-bin-percent	1095	1096	7
I-cv-bin-percent	1096	1097	%
O	1098	1101	for
O	1102	1105	the
O	1106	1113	control
O	1114	1119	group
O	1119	1120	;
O	1121	1123	OR
O	1124	1125	0
O	1125	1126	.
O	1126	1128	89
O	1128	1129	;
O	1130	1132	CI
O	1133	1134	0
O	1134	1135	.
O	1135	1137	27
O	1137	1138	-
O	1138	1139	2
O	1139	1140	.
O	1140	1142	90
O	1142	1143	;
O	1144	1145	P
O	1145	1146	=
O	1146	1147	0
O	1147	1148	.
O	1148	1150	84
O	1150	1151	)
O	1151	1152	.

O	1153	1156	Per
O	1156	1157	-
O	1157	1165	protocol
O	1166	1174	analysis
O	1175	1184	indicated
O	1185	1189	that
O	1190	1198	patients
O	1199	1202	who
O	1203	1211	received
O	1212	1215	DNA
O	1216	1220	test
O	1221	1228	results
O	1229	1235	before
O	1236	1243	surgery
O	1244	1245	(
B-iv-bin-abs	1245	1247	59
O	1248	1251	out
O	1252	1254	of
B-intervention-participants	1255	1258	178
O	1259	1264	women
O	1265	1267	in
O	1268	1271	the
O	1272	1276	RGCT
O	1277	1282	group
O	1282	1283	)
B-outcome	1284	1289	opted
I-outcome	1290	1293	for
I-outcome	1294	1300	direct
I-outcome	1301	1304	BLM
O	1305	1318	significantly
O	1319	1323	more
O	1324	1329	often
O	1330	1334	than
O	1335	1343	patients
O	1344	1347	who
O	1348	1356	received
O	1357	1362	usual
O	1363	1367	care
O	1368	1369	(
B-iv-bin-percent	1369	1371	22
I-iv-bin-percent	1371	1372	%
O	1373	1375	vs
B-cv-bin-percent	1376	1377	9
I-cv-bin-percent	1377	1378	.
I-cv-bin-percent	1378	1379	2
I-cv-bin-percent	1379	1380	%
O	1380	1381	;
O	1382	1384	OR
O	1385	1386	3
O	1386	1387	.
O	1387	1389	09
O	1389	1390	,
O	1391	1393	CI
O	1394	1395	1
O	1395	1396	.
O	1396	1398	15
O	1398	1399	-
O	1399	1400	8
O	1400	1401	.
O	1401	1403	31
O	1403	1404	,
O	1405	1406	P
O	1406	1407	=
O	1407	1408	0
O	1408	1409	.
O	1409	1411	03
O	1411	1412	)
O	1412	1413	.

O	1414	1422	Although
O	1423	1426	the
O	1427	1432	large
O	1433	1441	majority
O	1442	1444	of
O	1445	1453	patients
O	1454	1456	in
O	1457	1460	the
O	1461	1473	intervention
O	1474	1479	group
O	1480	1489	underwent
O	1490	1495	rapid
O	1496	1503	genetic
O	1504	1515	counselling
O	1515	1516	,
O	1517	1521	only
O	1522	1523	a
O	1524	1532	minority
O	1533	1541	received
O	1542	1545	DNA
O	1546	1550	test
O	1551	1558	results
O	1559	1565	before
O	1566	1573	surgery
O	1573	1574	.

O	1575	1579	This
O	1580	1583	may
O	1584	1591	explain
O	1592	1595	why
O	1596	1604	offering
O	1605	1609	RGCT
O	1610	1617	yielded
O	1618	1622	only
O	1623	1633	marginally
O	1634	1645	significant
O	1646	1657	differences
O	1658	1660	in
O	1661	1667	uptake
O	1668	1670	of
O	1671	1674	BLM
O	1674	1675	.

O	1676	1678	As
O	1679	1687	patients
O	1688	1691	who
O	1692	1700	received
O	1701	1704	DNA
O	1705	1709	test
O	1710	1717	results
O	1718	1724	before
O	1725	1732	surgery
O	1733	1737	were
O	1738	1742	more
O	1743	1749	likely
O	1750	1752	to
O	1753	1760	undergo
O	1761	1764	BLM
O	1764	1765	,
O	1766	1768	we
O	1769	1780	hypothesise
O	1781	1785	that
O	1786	1790	when
O	1791	1794	DNA
O	1795	1799	test
O	1800	1807	results
O	1808	1811	are
O	1812	1816	made
O	1817	1826	routinely
O	1827	1836	available
O	1837	1840	pre
O	1840	1841	-
O	1841	1848	surgery
O	1848	1849	,
O	1850	1854	they
O	1855	1859	will
O	1860	1864	have
O	1865	1866	a
O	1867	1871	more
O	1872	1883	significant
O	1884	1888	role
O	1889	1891	in
O	1892	1900	surgical
O	1901	1910	treatment
O	1911	1920	decisions
O	1920	1921	.
